UK markets closed

Oxurion NV (TBGNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.18000.0000 (0.00%)
At close: 11:49AM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.1800
Open2.1800
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.1800 - 2.1800
52-week range1.0000 - 3.3500
Volume100
Avg. volume17
Market cap83.477M
Beta (5Y monthly)0.99
PE ratio (TTM)N/A
EPS (TTM)-0.9050
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA

    Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidates that are targeting potential market opportunities of over USD 12 billion. Leuven, BE, Boston, MA, US – November 30, 2021 – 07.00 AM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of

  • Globe Newswire

    OXURION to Present at the Ophthalmology Day at BTIG

    Leuven, BELGIUM, Boston, MA, US - November 24, 2021 – 07.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, today announces its management will present and meet with investors at the Ophthalmology Day at BTIG: Ophthalmology Day at BTIG Tuesday, November 30, 2021Fireside Chat: 8:30 AM ET For more information, please visit Oxurion’s events page

  • Globe Newswire

    OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures

    Provides Additional Capital to further Develop the Company’s Innovative Pipeline of Novel Clinical Assets, THR-687 and THR-149 Leuven, BE, Boston, MA, US – November 22, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces it has entered into a EUR 10 million loan agreement with Kreos Capital and Pontifax Ventures, which will